Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 6;55(6):2422-2439.
doi: 10.1080/03036758.2024.2406824. eCollection 2025.

The history and future of pharmacogenetics in Aotearoa/New Zealand

Affiliations
Review

The history and future of pharmacogenetics in Aotearoa/New Zealand

Martin A Kennedy. J R Soc N Z. .

Abstract

Pharmacogenetics is the study of genetic variants in genes which may impact on the outcome of drug treatment, either through safety considerations (occurrence of adverse drug reactions or therapeutic failure) or altered drug pharmacokinetics. This paper provides a brief history of pharmacogenetics research in the Aotearoa/New Zealand context, and a commentary on our current state. Factors that have limited translation of pharmacogenetic knowledge into ou r healthcare system are considered, and possible solutions to these are proposed. Pharmacogenetic knowledge has long been invoked as a way to improve the safety and success of drug prescribing, but (with some notable exceptions) it has largely failed to achieve this promise. Several barriers to clinical implementation need to be overcome to ensure that pharmacogenetics becomes a key component of precision health for all people in Aotearoa/New Zealand.

Keywords: Adverse drug reaction; direct-to-consumer; drug prescribing; genetic test; personalised medicine; pharmacogenomics.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Similar articles

References

    1. Alrajeh KY, Roman YM.. 2022. The frequency of major CYP2C19 genetic polymorphisms in women of Asian, Native Hawaiian and Pacific Islander subgroups. Per Med. 19:327–339. doi: 10.2217/pme-2021-0175. - DOI - PMC - PubMed
    1. Alvarellos ML, Krauss RM, Wilke RA, Altman RB, Klein TE.. 2016. PharmGKB summary: very important pharmacogene information for RYR1. Pharmacogenet Genomics. 26:138–144. doi: 10.1097/FPC.0000000000000198. - DOI - PMC - PubMed
    1. Australasia RCoPo . 2024. Pharmacogenomic Indications in Australia. Australia; [accessed 18/05/2024]. https://www.rcpa.edu.au/Library/Practising-Pathology/Pharmacogenomic-Ind....
    1. Berm EJ, Looff M, Wilffert B, Boersma C, Annemans L, Vegter S, Boven JF, Postma MJ.. 2016. Economic evaluations of pharmacogenetic and pharmacogenomic screening tests: a systematic review. Second update of the literature. PLoS One. 11:e0146262. - PMC - PubMed
    1. Botton MR, Whirl-Carrillo M, Del Tredici AL, Sangkuhl K, Cavallari LH, Agundez JAG, Duconge J, Lee MTM, Woodahl EL, Claudio-Campos K, et al. 2021. PharmVar GeneFocus: CYP2C19. Clin Pharmacol Ther. 109:352–366. doi: 10.1002/cpt.1973. - DOI - PMC - PubMed

LinkOut - more resources